The generation of stable, high MAb expressing CHO cell lines based on the artificial chromosome expression (ACE) technology
Open accessAbstract
The manufacture of recombinant proteins at industrially relevant levels requires technologies that can engineer stable, high expressing cell lines rapidly, reproducibly and with relative ease. Commonly used methods incorporate transfection of mammalian cell lines with plasmid DNA containing the gene of interest. Identifying stable high expressing transfectants is normally laborious and time consuming. To improve this process, the ACE System has been developed based on pre‐engineered artificial chromosomes with multiple recombination acceptor sites. This system allows for the targeted transfection of single or multiple genes and eliminates the need for random integration into native host chromosomes. To illustrate the utility of the ACE System in generating stable, high expressing cell lines, CHO based candidate cell lines were generated to express a human monoclonal IgG1 antibody. Candidate cell lines were generated in under 6 months and expressed over 1 g/L and with specific productivities of up to 45 pg/cell/day under non‐fed, non‐optimized shake flask conditions. These candidate cell lines were shown to have stable expression of the monoclonal antibody for up to 70 days of continuous culture. The results of this study demonstrate that clonal, stable monoclonal antibody expressing CHO based cell lines can be generated by the ACE System rapidly and perform competitively with those cell lines generated by existing technologies. The ACE System, therefore, provides an attractive and practical alternative to conventional methods of cell line generation. Biotechnol. Bioeng. 2009; 104: 540–553 © 2009 Wiley Periodicals, Inc.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ACE technology was shown to be effective for establishing CHO cell lines producing respectable titers of monoclonal antibody.
“It was shown to be effective for establishing CHO cell lines producing respectable titers of monoclonal antibody (Lindenbaum et al., 2004;Kennard et al., 2009;Kennard 2011).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Kennard et al., 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 2
- Kennard ML, Goosney DG, Ledebur HC. 2007. Generating stable, high- expressing cell lines for recombinant protein manufacture. BioPharm Int 20(3):52-59.
- Nott A, Meislin S, Moore M. 2003. A quantitative analysis of intron effects on mammalian gene expression. RNA 9(5):607-617.
Cited by
Sorted by citations
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · see citing works
- Authors
- Kennard, M. L., Goosney, D. L., Monteith, D., Zhang, L., Moffat, M., Fischer, D., & Mott, J.
- Affiliations
- Canadian Institutes of Health Research (CA)
- Centre for Drug Research and Development (CA)
- Pfizer (United States) (US)
- Corresponding author
- Kennard, Malcolm L.
- ORCID
- Kennard, Malcolm L.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2009-06-25
- Volume
- 104
- Issue
- 3
- Pages
- 540-553
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2110027404
- Cited by
- 52
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 8 · 2013: 4 · 2012: 4
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Biotechnology and Bioengineering (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Keywords
- monoclonal antibody expression, CHO cells, recombinant protein expression, transfection, IgG1 monoclonal antibody, expression stability
- MeSH terms
- Animals, Antibodies, Monoclonal, Cricetulus, Genetic Vectors, Cricetinae, Humans, Immunoglobulin G, Recombinant Proteins, Transfection, Gene Expression, CHO Cells, Chromosomes, Artificial, Genomic Instability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review